Stockreport

Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

JUNO THERAPEUTICS  (JUNO) 
Last juno therapeutics earnings: 11/1 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.junotherapeutics.com/investor-relations
PDF —74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of c [Read more]